Medicines for Europe, Belgium
Director Biosimilars Policy & Science
Leading the Biosimilar Medicines Group, a sector group of Medicines for Europe, Julie aims at creating and nurturing dialogue with experts and partners across healthcare systems. The main objectives of the Biosimilar Medicines Group are to support and facilitate the design, evolution and implementation of policies aimed at fostering greater access to biologic therapies and other healthcare products and services, with biosimilar medicines use as catalyst for smart investment in health. Since January 2019 on, she has been co-chair of the Biosimilars committee of the International Generic and Biosimilar medicines Association (IGBA) focusing on convergence of global policies and standards.